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Estrogen Therapy and Coronary-Artery Calcification
Manson JE, Allison MA, Rossouw JE, et al; and the WHI-CACS Investiga-
tors. N Engl J Med 2007;356:2591-602.
Conclusion: Calcified plaque in coronary arteries of women is de-
creased by estrogen therapy compared with placebo.
Summary: Coronary artery calcified plaque is a marker of overall
atherosclerotic burden and is a predictor of future cardiovascular events. In
this study, the authors examined the relationship between coronary artery
calcification and estrogen therapy. This was a substudy of the Women’s
Health Initiative comparing conjugated equine estrogens (0.625 mg/d)
with placebo in women who had undergone hysterectomy.
Computed tomography (CT) of the heart was performed in 1064
women aged 50-59 years at the time of randomization in the Women’s
Health Initiative. Cardiac CT was performed after a mean of 7.4 years of
treatment. Coronary artery calcification was measured by Agatston scores.
Measurements were performed at a central reading center blinded to ran-
domization status.
Women receiving estrogens had lower mean coronary artery calcifi-
cation scores than those receiving placebo (83.1 vs 123.1, P  .02).
Adjusting for coronary risk factors, the odds ratios (95% confidence
intervals [CI]) for coronary artery calcium scores of 0, 10, and 100
in the group receiving estrogen compared with placebo were 0.78
(0.58-1.04), 0.74 (0.55-0.99), and 0.69 (0.48-0.98), respectively. In
women with at least 80% adherence to the study estrogen or placebo
dosages, the odds ratios were 0.64 (P  .01), 0.55 (P  .001), and 0.46
(P  .001). In an intention-to-treat analysis, the odds ratio for coronary
artery calcification scores of 300 vs 10 was 0.58 (P  .03). Among
women with at least 80% adherence, the odds ratio for coronary artery
calcification scores of 300 vs 10 was 0.39 (P  .004).
Comment: The data suggest estrogen therapy in middle-aged
women (therapy was initiated in women 50-59 years old) may result in
reduced plaque burden in the coronary arteries and, by inference, a
reduction in subclinical coronary artery disease and overall atheroscle-
rotic disease. The biologic effects of estrogen are complicated, and
estrogen replacement therapy may be associated with adverse venous
events. The overall benefit of estrogen replacement therapy for cardio-
vascular disease can only be established through large scale randomized
trials with clinical end points.
Oral Anticoagulant and Antiplatelet Therapy in Peripheral Arterial
Disease
The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. N Engl J
Med 2007;357:217-27.
Conclusion:The combination of an oral anticoagulant and antiplatelet
therapy is no more effective than antiplatelet therapy alone in preventing
major cardiovascular complications in patients with peripheral arterial dis-
ease (PAD). Combination therapy is associated with an increase in life-
threatening bleeding.
Summary: Antiplatelet drugs are known to reduce the risk of myocar-
dial infarction (MI), stroke, and death from cardiovascular causes in patients
with PAD. It is unknown if oral anticoagulant agents can provide added
benefit to antiplatelet drugs in reducing these complications. The authors
sought to compare patients with PAD treated with combination therapy vs
an antiplatelet agent alone. Those patients treated with combination therapy
had a target international normalized ratio of 2.0 to 3.0 for oral anticoagu-
lant therapy. One primary outcome was MI, stroke, or death from cardio-
vascular causes. The second primary outcome was MI, stroke, severe isch-
emia of the periphery or coronary arteries leading to an urgent intervention,
or death from cardiovascular causes.
This was a randomized, open-label, clinical trial at 80 centers from
Canada, Poland, Hungary, the Ukraine, China, the Netherlands, and Aus-
tralia. Patients were men and women aged 35 to 85 years with known PAD
defined as evidence of atherosclerosis of the lower extremities, carotid, or
subclavian arteries. Excluded patients had an indication for oral anticoagu-
lation therapy other than participation in this study, patients receiving
dialysis, those whowere actively bleeding or at high risk of bleeding, or those
who had had a stroke 6 months before enrollment.
A total of 2161 patients were enrolled and randomized. Mean fol-
low-up was 35 months. Stroke, MI, or death from a cardiovascular cause
occurred in 132 of 1080 patients receiving combination therapy and in 144
of 1081 patients receiving antiplatelet therapy (12.2% vs 13.3%; relative risk,
0.92; 95% confidence interval [CI], 0.73-1.16; P .48). MI, stroke, severe
ischemia requiring urgent intervention, or death from cardiovascular causes
occurred in 172 patients receiving combination therapy vs 188 patients
receiving antiplatelet therapy (15.9% vs 17.4%; relative risk, 0.91; 95% CI,
0.74-1.12, P  .37). There was a higher incidence of life-threatening
bleeding in the patients receiving combination therapy (4.0% vs 1.2%;
relative risk, 3.41; 95% CI, 1.84-6.35, P  .001).
Comment: The results are consistent with a previous study published
in Journal of Vascular Surgery detailing the results of Department of Veter-
an’s Affairs cooperative study (J Vasc Surg 2002;35:413-21). It is clearly not
indicated to add oral anticoagulation therapy to antiplatelet therapy in
patients with PAD where the sole indication is an attempt to reduce stroke,
MI, death from cardiovascular causes, or prevent acute ischemic events of
native arteries. Data do not apply to prevention of occlusion of vascular
grafts.
Consistent Platelet Inhibition During Long-TermMaintenance Clopi-
dogrel Therapy Among Three Hundred Fifty-Nine Compliant Outpa-
tients with Documented Vascular Disease
Serebruany VL, Malinin AI, Atar D, et al. Am Heart J 2007;153:371-7.
Conclusion: Long-term therapy with clopidogrel provides more con-
sistent platelet inhibition than that observed following initiation of therapy
after acute vascular events.
Summary: There have been conflicting reports on the effects of
clopidogrel therapy on platelet inhibition after an acute vascular event. Some
reports have documented a high incidence of clopidogrel nonresponsive-
ness, but these reports have been complicated by varying definitions and
different platelet aggregation tests. This study sought to assess the effect of
clopidogrel on platelet characteristics in outpatients who received mainte-
nance dosages of clopidogrel (75 mg/d) for30 days. This was a secondary
analysis of presumably compliant patients treated with clopidogrel and
aspirin. The patient cohort consisted of 237 who had undergone coronary
artery stenting and 122 who had sustained an ischemic stroke.
Themean duration of treatment was 5.8months (range, 1-21months).
All patients exhibited inhibition of adenosine diphosphate-induced platelet
activation (mean, 52.9%; range, 36%-70%) compared with preclopidogrel
measurements. A diminished expression of platelet-endothelial cell adhesion
molecule 1 (r  0.75), glycoprotein 2B-3A (r  0.62), and protease-
activated receptor 1 (r 0.71) were all correlated with inhibition of platelet
aggregation. No patients were found to have platelet hyporesponsiveness or
profound inhibition of platelet activity.
Comment: The wide response variability to clopidogrel in the acute
setting does not hold up with more long-term administration of the drug.
The article suggests that problems related to clopidogrel resistance may be
exaggerated by previous emphasis on short-term rather than long-term
maintenance data.
Anticoagulation for Three vs. Six Months in Patients With Deep Vein
Thrombosis or Pulmonary Embolism, or Both: Randomized Trial
Campbell IA, Bentley DP, Prescott RJ, et al. BMJ 2007;334:674-7.
Conclusion: There is little advantage in increasing the duration of
anticoagulation from 3 to 6 months in patients with deep vein thrombosis
(DVT) or pulmonary embolism (PE) and no known risk factors for recur-
rence.
Summary: This was a multicenter prospective randomized study with
1 year of follow-up. The objective was to determine the optimal duration of
anticoagulation therapy after an episode of DVT or PE. The study took place
in 46 hospitals in the United Kingdom and involved patients aged18 years
old randomized to either 3 or 6months of warfarin therapy beginning on the
first of 5 scheduled days of heparin administration after the diagnosis of
venous thromboembolism (VTE). The target international normalized ratio
was 2.0 to 3.5. There were 369 patients randomized to 3 months and 380
randomized to 6 months of oral anticoagulant therapy. Main outcomes
measures included death from VTE, failure to resolve, extension of clot,
recurrence of VTE during treatment, recurrence after treatment, and major
hemorrhage during treatment.
Two of the patients allocated to 3 months of treatment died from VTE
during or after treatment. Three patients allocated to 6 months of treatment
died secondary to VTE.During treatment in the 3-month group, VTE failed
to resolve, extended, or recurred in six patients. There were no fatal
consequences. In the 6-month group, VTE failed to resolve, extended, or
recurred in 10 patients, without fatal consequences.
After completion of treatment, there were 23 non-fatal recurrences of
VTE in the 3-month group and 16 non-fatal recurrences of VTE in the
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